Rocuronium and sugammadex as a novel management strategy in a patient with plasmacholinesterase deficiency presenting for electroconvulsive therapy

Anaesthesia and Intensive Care

Volumn 39, Issue 4, 2011, Pages 764-765

  Eissa, S ^a   Lim, K S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ROCURONIUM; SUGAMMADEX; SUXAMETHONIUM; ANDROSTANE DERIVATIVE; CHOLINESTERASE; GAMMA CYCLODEXTRIN DERIVATIVE; NEUROMUSCULAR DEPOLARIZING AGENT;

ADULT; ASSISTED VENTILATION; CASE REPORT; DRUG COST; ELECTROCONVULSIVE THERAPY; ENZYME DEFICIENCY; FEMALE; HUMAN; LETTER; NEUROMUSCULAR BLOCKING; NEUROMUSCULAR FUNCTION; PATIENT MONITORING; PLASMACHOLINESTERASE DEFICIENCY; DRUG ANTAGONISM; MIDDLE AGED;

ANDROSTANOLS; CHOLINESTERASES; ELECTROCONVULSIVE THERAPY; FEMALE; GAMMA-CYCLODEXTRINS; HUMANS; MIDDLE AGED; NEUROMUSCULAR BLOCKADE; NEUROMUSCULAR DEPOLARIZING AGENTS;

EID: 80051926994     PISSN: 0310057X     EISSN: 14480271     Source Type: Journal    
DOI: None     Document Type: Letter

References (6)

1. Sarpel Y, Torul E, Herdem M, Tan I, Baytok G. Central acetabular fracture-dislocation following electroconvulsive therapy: report of two similar cases. J Trauma 1996; 41:342-344.
2. Davis L, Britten JJ, Morgan M. Cholinesterase. Its significance in anaesthetic practice. Anaesthesia 1997; 52:244-260.
3. Stack CG, Abernethy MH, Thacker M. Atracurium for ECT in plasma cholinesterase deficiency. Br J Anaesth 1988; 60:244-245.
4. Riesenman JP, Mathew RT. Heterozygous atypical cholinesterase: management during ECT. Convuls Ther 1992; 8:280-284.
5. Sacan O, White PF, Tufanogullari B, Klein K. Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edrophoniumatropine. Anesth Analg 2007; 104:569-574.
6. Flockton EA, Mastronardi P, Hunter JM, Gomar C, Mirakhur RK, Aguilera L et al. Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine. Br J Anaesth 2008; 100:622-630.